Rapport Therapeutics
Rapport Therapeutics Inc is an American clinical-stage biopharmaceutical enterprise headquartered in Boston, Massachusetts. The company specializes in the discovery and development of precision neuroscience therapeutics targeting receptor-associated proteins for the treatment of central nervous system (CNS) disorders, including epilepsy, chronic pain, and psychiatric conditions. Its proprietary discovery platform identifies novel drug targets with high anatomical precision. Principal revenue is currently earned through strategic pharmaceutical research partnerships, milestone payments, and capital financing arrangements. Rapport Therapeutics Inc is publicly listed on the Nasdaq Stock Market.
3 of the funds FundTelligence covers report a position in Rapport Therapeutics.
- Legal name
- RAPPORT THERAPEUTICS
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
Funds holding Rapport Therapeutics
- Swedbank Robur Healthcare — Swedbank · 0.2 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.08 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)